6:05 PM
 | 
Sep 17, 2008
 |  BC Extra  |  Company News

NICE issues Crohn's guidance

The U.K.'s NICE issued a preliminary appraisal recommending against the use of Humira adalimumab from Abbott (NYSE:ABT) and Remicade infliximab from Johnson & Johnson (NYSE:JNJ) and Schering-Plough (NYSE:SGP) as regular maintenance treatment to...

Read the full 167 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >